Histone deacetylase inhibitors induce thymidine phosphorylase expression in cultured breast cancer cell lines

Oncology Reports

Volumn 26, Issue 2, 2011, Pages 309-314

  Puppin, Cinzia ^a   Puglisi, Fabio ^b   Pandolfi, Maura ^a   Di Loreto, Carla ^a   Damante, Giuseppe ^a,b  

^a UNIVERSITY OF UDINE   (Italy)

^b UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

Breast cancer; Histone deacetylase inhibitor; Thymidine phosphorylase

Indexed keywords

MESSENGER RNA; THYMIDINE PHOSPHORYLASE; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA; VORINOSTAT;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DEOXYCYTIDINE; DRUG SYNERGISM; FEMALE; FLUOROURACIL; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; IMMUNOHISTOCHEMISTRY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THYMIDINE PHOSPHORYLASE;

EID: 79958224429     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1310     Document Type: Article

References (31)

1. Friedkin M and Roberts D: The enzymatic synthesis of nucleosides. IL Thymidine and related pyrimidine nucleosides. J Biol Chem 207: 245-256, 1954.
2. Miyazono K, Okabe T, Urabe A, Takaku F and Heldin CH: Purification and properties of an endothelial cell growth factor from human platelets. J Biol Chem 262: 4098-4103, 1987. (Pubitemid 17102635)
3. Ishikawa F, Miyazono K, Hellman U, et al: Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 338: 557-562, 1989. (Pubitemid 19102308)
4. Toi M, Rahman MA, Bando M and Chow LW: Thymidine Phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment. Lancet Oncol 6: 158-166, 2005. (Pubitemid 40309127)
5. Miwa M, Ura M, Nishida M, et al: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34: 1274-1281, 1998. (Pubitemid 28342121)
6. Gotanda T, Haraguchi M, Tachiwada T, et al: Molecular basis for the involvement of thymidine Phosphorylase in cancer invasion. Int J Mol Med 17: 1085-1091, 2006.
7. Iltzsch MH, El Kouni MH and Cha S: Kinetic studies of thymidine Phosphorylase from mouse liver. Biochemistry 24: 6799-6807, 1985. (Pubitemid 16170208)
8. Moghaddam A, Zhang HT, Fan TP, et al: Thymidine Phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci USA 92: 998-1002, 1995.
9. Li H, Suo Z, Zhang Y, Risberg B, et al: The prognostic significance of thymidine Phosphorylase, thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expressions in breast carcinomas. Histol Histopathol 19: 129-136, 2004. (Pubitemid 38111257)
10. Yang Q, Barbareschi M, Mori I, et al: Prognostic value of thymidine phosphorylase expression in breast carcinoma. Int J Cancer 97: 512-517, 2002. (Pubitemid 34027812)
11. Tominaga T, Toi M and Abe O; 5′-BC Study Group: Prognostic and predictive value of thymidine Phosphorylase activity in early-stage breast cancer patients. Clin Breast Cancer 3: 55-64, 2002. (Pubitemid 34546073)
12. Liekens S, Bronckaers A, Pérez-Pérez MJ and Balzarini J: Targeting platelet-derived endothelial cell growth factor/ thymidine Phosphorylase for cancer therapy. Biochem Pharmacol 74: 1555-1567, 2007. (Pubitemid 47614960)
13. Meropol NJ, Gold PJ, Diasio RB, et al: Thymidine Phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 24: 4069-4077, 2006. (Pubitemid 46622281)
14. Layman RM, Thomas DG, Griffith KA, et al: Neoadjuvant docetaxel and capecitabine and the use of thymidine Phosphorylase as a predictive biomarker in breast cancer. Clin Cancer Res 13: 4092-4097, 2007. (Pubitemid 47105970)
15. Puglisi F, Cardellino GG, Crivellari D, et al: Thymidine Phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer. Ann Oncol 19: 1541-1546, 2008.
16. Andreetta C, Puppin C, Minisini A, et al: Thymidine Phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer. Ann Oncol 20: 265-271, 2009.
17. Koopman M, Venderbosch S, van Tinteren H, et al: Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study. Eur J Cancer 45: 1999-2006, 2009.
18. Ruckhäberle E, Karn T, Engels K, et al: Prognostic impact of thymidine Phosphorylase expression in breast cancer - comparison of microarray and immunohistochemical data. Eur J Cancer 46: 549-557, 2010.
19. Beillard E, Pallisgaard N, van der Velden VH, et al: Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using real-time quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia 17: 2474-2486, 2003. (Pubitemid 38072587)
20. Bertrand P: Inside HDAC with HDAC inhibitors. Eur J Med Chem 45: 2095-2116, 2010.
21. Kelly WK and Marks PA: Drug insight: Histone deacetylase inhibitors - development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2: 150-157, 2005. (Pubitemid 40823166)
22. Zhu GH, Lenzi M and Schwartz EL: The Sp1 transcription factor contributes to the tumor necrosis factor-induced expression of the angiogenic factor thymidine Phosphorylase in human colon carcinoma cells. Oncogene 21: 8477-8485, 2002. (Pubitemid 36054888)
23. Xu WS, Parmigiani RB and Marks PA: Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26: 5541-5552, 2007. (Pubitemid 47255934)
24. Richon V: Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor. Br J Cancer 95: S2-S6, 2006.
25. Duvic M, Talpur R, Ni X, et al: Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109: 31-39, 2007.
26. Wong ST: Emerging treatment combinations: integrating therapy into clinical practice. Am J Health Syst Pharm 66: S9-S14, 2009.
27. Kristensen LS, Nielsen HM and Hansen LL: Epigenetics and cancer treatment. Eur J Pharmacol 625: 131-142, 2009.
28. Ellis L, Hammers H and Pili R: Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett 280: 145-153, 2009.
29. Marchion DC, Bicaku E, Daud AI, Richon V, Sullivan DM and Munster PN: Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem 92: 223-237, 2004.
30. Catalano MG, Fortunati N, Pugliese M, et al: Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. J Endocrinol 191: 465-472, 2006. (Pubitemid 44830622)
31. Marchion DC, Bicaku E, Turner JG, Schmitt ML, Morelli DR and Munster PN: HDAC2 regulates chromatin plasticity and enhances DNA vulnerability. Mol Cancer Ther 8: 794-801, 2009.